Isocitrate dehydrogenase (IDH) mutations are highly frequent in glioma, producing high levels of the oncometabolite D-2-hydroxyglutarate (D-2HG). Hence, D-2HG represents a valuable imaging marker for IDH mutant glioma.

Li et al. developed and evaluated a super-resolution 3D MR spectroscopy strategy to map D-2HG and tumor metabolism in IDH-mutated human glioma.

Between March and September 2018, participants with IDH1-mutated gliomas and healthy participants were prospectively scanned with a 3-T whole-brain 3D MR spectroscopic imaging protocol optimized for D-2HG. The acquired D-2HG maps with a voxel size of 5.2 × 5.2 × 12 mm were upsampled to a voxel size of 1.7 × 1.7 × 3 mm using a super-resolution method that combined weighted total variation, feature-based nonlocal means, and high-spatial-resolution anatomic imaging priors. Validation with simulated healthy and patient data and phantom measurements was also performed. The Mann-Whitney U test was used to check that the proposed super-resolution technique yields the highest peak signal-to-noise ratio and structural similarity index. Three participants with IDH1-mutated gliomas (mean age, 50 years ± 21 [standard deviation]; two men) and three healthy participants (mean age, 32 years ± 3; two men) were scanned. Twenty healthy participants (mean age, 33 years ± 5; 16 men) underwent a simulation of upsampled MR spectroscopic imaging. Super-resolution upsampling improved peak signal-to-noise ratio and structural similarity index by 62% (P < .05) and 7.3% (P < .05), respectively, for simulated data when compared with spline interpolation. Correspondingly, the proposed method significantly improved tissue contrast and structural information for the acquired 3D MR spectroscopic imaging data.

High-spatial-resolution whole-brain D-2-hydroxyglutarate imaging is possible in isocitrate dehydrogenase 1-mutated human glioma by using a super-resolution framework to upsample three-dimensional MR spectroscopic images acquired at lower resolution 1).

A study showed some evidence that both IDH1 mutation and 2-HG can lead to EMT-like phenotype and proliferation and migration in glioma cells. EMT-like biomarkers changed in IDH1 mutation cells generated via lentiviral transduction technology or treated in 2-HG 2).

Gas chromatography time-of-flight mass spectrometry was applied to CSF samples collected from 15 consecutive high-grade aSAH patients (modified Fisher grade 3 or 4). Collected CSF samples were analyzed at two time points (admission and the anticipated vasospasm timeframe). Metabolite levels at both time points were compared and correlated with vasospasm status and Glasgow Outcome Scale (GOS) of patients at 1 year post-aSAH. Significance level was defined as p < 0.05 with false discovery rate correction for multiple comparisons.

Of 97 metabolites identified, 16 metabolites, primarily free amino acids, significantly changed between the two time points. These changes were magnified in modified Fisher grade 4 compared with grade 3. Six metabolites (2-hydroxyglutarate, tryptophan, glycine, proline, isoleucine, and alanine) correlated with GOS at 1 year post-aSAH independent of vasospasm status. When predicting patients who had low disability (GOS 5 vs. GOS ≤4), 2-hydroxyglutarate had a sensitivity and specificity of 0.89 and 0.83 respectively.

This preliminary study suggests that specific metabolite changes occur in the brain during the course of aSAH and that quantification of specific CSF metabolites may be used to predict long-term outcome in patients with aSAH. This is the first study to implicate 2-hydroxyglutarate, a known marker of tissue hypoxia, in aSAH pathogenesis 3).

Last update 09.01.2020

2: Huang LE. Friend or foe-IDH1 mutations in glioma 10 years on. Carcinogenesis. 2019 Nov 25;40(11):1299-1307. doi: 10.1093/carcin/bgz134. PubMed PMID: 31504231; PubMed Central PMCID: PMC6875900.

3: Zhang Y, Pusch S, Innes J, Sidlauskas K, Ellis M, Lau J, El-Hassan T, Aley N, Launchbury F, Richard-Loendt A, deBoer J, Chen S, Wang L, von Deimling A, Li N, Brandner S. Mutant IDH Sensitizes Gliomas to Endoplasmic Reticulum Stress and Triggers Apoptosis via miR-183-Mediated Inhibition of Semaphorin 3E. Cancer Res. 2019 Oct 1;79(19):4994-5007. doi: 10.1158/0008-5472.CAN-19-0054. Epub 2019 Aug 7. PubMed PMID: 31391185.

4: Miyata S, Tominaga K, Sakashita E, Urabe M, Onuki Y, Gomi A, Yamaguchi T, Mieno M, Mizukami H, Kume A, Ozawa K, Watanabe E, Kawai K, Endo H. Comprehensive Metabolomic Analysis of IDH1(R132H) Clinical Glioma Samples Reveals Suppression of β-oxidation Due to Carnitine Deficiency. Sci Rep. 2019 Jul 5;9(1):9787. doi: 10.1038/s41598-019-46217-5. PubMed PMID: 31278288; PubMed Central PMCID: PMC6611790.

5: Xu H, Xia YK, Li CJ, Zhang JY, Liu Y, Yi W, Qin ZY, Chen L, Shi ZF, Quan K, Yang ZX, Guan KL, Xiong Y, Ng HK, Ye D, Hua W, Mao Y. Rapid diagnosis of IDH1-mutated gliomas by 2-HG detection with gas chromatography mass spectrometry. Lab Invest. 2019 Apr;99(4):588-598. doi: 10.1038/s41374-018-0163-z. Epub 2018 Dec 20. PubMed PMID: 30573870.

6: Wenger KJ, Hattingen E, Harter PN, Richter C, Franz K, Steinbach JP, Bähr O, Pilatus U. Fitting algorithms and baseline correction influence the results of non-invasive in vivo quantitation of 2-hydroxyglutarate with (1) H-MRS. NMR Biomed. 2019 Jan;32(1):e4027. doi: 10.1002/nbm.4027. Epub 2018 Nov 20. PubMed PMID: 30457203.

7: McBrayer SK, Mayers JR, DiNatale GJ, Shi DD, Khanal J, Chakraborty AA, Sarosiek KA, Briggs KJ, Robbins AK, Sewastianik T, Shareef SJ, Olenchock BA, Parker SJ, Tateishi K, Spinelli JB, Islam M, Haigis MC, Looper RE, Ligon KL, Bernstein BE, Carrasco RD, Cahill DP, Asara JM, Metallo CM, Yennawar NH, Vander Heiden MG, Kaelin WG Jr. Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. Cell. 2018 Sep 20;175(1):101-116.e25. doi: 10.1016/j.cell.2018.08.038. Epub 2018 Sep 13. PubMed PMID: 30220459; PubMed Central PMCID: PMC6219629.

8: Park GHJ, Yang SH, Baek HM. 900MHz 1H-/13C-NMR analysis of 2-hydroxyglutarate and other brain metabolites in human brain tumor tissue extracts. PLoS One. 2018 Sep 7;13(9):e0203379. doi: 10.1371/journal.pone.0203379. eCollection 2018. PubMed PMID: 30192797; PubMed Central PMCID: PMC6128478.

9: Yamashita AS, da Costa Rosa M, Borodovsky A, Festuccia WT, Chan T, Riggins GJ. Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide. Neuro Oncol. 2019 Feb 14;21(2):189-200. doi: 10.1093/neuonc/noy146. PubMed PMID: 30184215; PubMed Central PMCID: PMC6374765.

10: Ballester LY, Lu G, Zorofchian S, Vantaku V, Putluri V, Yan Y, Arevalo O, Zhu P, Riascos RF, Sreekumar A, Esquenazi Y, Putluri N, Zhu JJ. Analysis of cerebrospinal fluid metabolites in patients with primary or metastatic central nervous system tumors. Acta Neuropathol Commun. 2018 Aug 31;6(1):85. doi: 10.1186/s40478-018-0588-z. PubMed PMID: 30170631; PubMed Central PMCID: PMC6117959.

11: Bunse L, Pusch S, Bunse T, Sahm F, Sanghvi K, Friedrich M, Alansary D, Sonner JK, Green E, Deumelandt K, Kilian M, Neftel C, Uhlig S, Kessler T, von Landenberg A, Berghoff AS, Marsh K, Steadman M, Zhu D, Nicolay B, Wiestler B, Breckwoldt MO, Al-Ali R, Karcher-Bausch S, Bozza M, Oezen I, Kramer M, Meyer J, Habel A, Eisel J, Poschet G, Weller M, Preusser M, Nadji-Ohl M, Thon N, Burger MC, Harter PN, Ratliff M, Harbottle R, Benner A, Schrimpf D, Okun J, Herold-Mende C, Turcan S, Kaulfuss S, Hess-Stumpp H, Bieback K, Cahill DP, Plate KH, Hänggi D, Dorsch M, Suvà ML, Niemeyer BA, von Deimling A, Wick W, Platten M. Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. Nat Med. 2018 Aug;24(8):1192-1203. doi: 10.1038/s41591-018-0095-6. Epub 2018 Jul 9. PubMed PMID: 29988124.

12: Steel A, Chiew M, Jezzard P, Voets NL, Plaha P, Thomas MA, Stagg CJ, Emir UE. Metabolite-cycled density-weighted concentric rings k-space trajectory (DW-CRT) enables high-resolution 1 H magnetic resonance spectroscopic imaging at 3-Tesla. Sci Rep. 2018 May 17;8(1):7792. doi: 10.1038/s41598-018-26096-y. PubMed PMID: 29773892; PubMed Central PMCID: PMC5958083.

13: Jiang B, Zhao W, Shi M, Zhang J, Chen A, Ma H, Suleman M, Lin F, Zhou L, Wang J, Zhang Y, Liu M, Wen S, Ouyang C, Wang H, Huang X, Zhou H, Li Q. IDH1 Arg-132 mutant promotes tumor formation through down-regulating p53. J Biol Chem. 2018 Jun 22;293(25):9747-9758. doi: 10.1074/jbc.RA117.001385. Epub 2018 May 9. PubMed PMID: 29743236; PubMed Central PMCID: PMC6016470.

14: Kanamori M, Maekawa M, Shibahara I, Saito R, Chonan M, Shimada M, Sonoda Y, Kumabe T, Watanabe M, Mano N, Tominaga T. Rapid detection of mutation in isocitrate dehydrogenase 1 and 2 genes using mass spectrometry. Brain Tumor Pathol. 2018 Apr;35(2):90-96. doi: 10.1007/s10014-018-0317-0. Epub 2018 Apr 18. PubMed PMID: 29671246.

15: Andronesi OC, Arrillaga-Romany IC, Ly KI, Bogner W, Ratai EM, Reitz K, Iafrate AJ, Dietrich J, Gerstner ER, Chi AS, Rosen BR, Wen PY, Cahill DP, Batchelor TT. Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate. Nat Commun. 2018 Apr 16;9(1):1474. doi: 10.1038/s41467-018-03905-6. PubMed PMID: 29662077; PubMed Central PMCID: PMC5902553.

16: Linninger A, Hartung GA, Liu BP, Mirkov S, Tangen K, Lukas RV, Unruh D, James CD, Sarkaria JN, Horbinski C. Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system. Neuro Oncol. 2018 Aug 2;20(9):1197-1206. doi: 10.1093/neuonc/noy051. PubMed PMID: 29660019; PubMed Central PMCID: PMC6071651.

17: Li T, Cox CD, Ozer BH, Nguyen NT, Nguyen HN, Lai TJ, Li S, Liu F, Kornblum HI, Liau LM, Nghiemphu PL, Cloughesy TF, Lai A. D-2-Hydroxyglutarate Is Necessary and Sufficient for Isocitrate Dehydrogenase 1 Mutant-Induced MIR148A Promoter Methylation. Mol Cancer Res. 2018 Jun;16(6):947-960. doi: 10.1158/1541-7786.MCR-17-0367. Epub 2018 Mar 15. PubMed PMID: 29545476; PubMed Central PMCID: PMC5984679.

18: Longuespée R, Wefers AK, De Vita E, Miller AK, Reuss DE, Wick W, Herold-Mende C, Kriegsmann M, Schirmacher P, von Deimling A, Pusch S. Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry. Acta Neuropathol Commun. 2018 Mar 2;6(1):21. doi: 10.1186/s40478-018-0523-3. PubMed PMID: 29499756; PubMed Central PMCID: PMC5834865.

19: Berrington A, Voets NL, Larkin SJ, de Pennington N, Mccullagh J, Stacey R, Schofield CJ, Jezzard P, Clare S, Cadoux-Hudson T, Plaha P, Ansorge O, Emir UE. A comparison of 2-hydroxyglutarate detection at 3 and 7 T with long-TE semi-LASER. NMR Biomed. 2018 Mar;31(3). doi: 10.1002/nbm.3886. Epub 2018 Jan 5. PubMed PMID: 29315915.

20: Tiburcio PDB, Xiao B, Berg S, Asper S, Lyne S, Zhang Y, Zhu X, Yan H, Huang LE. Functional requirement of a wild-type allele for mutant IDH1 to suppress anchorage-independent growth through redox homeostasis. Acta Neuropathol. 2018 Feb;135(2):285-298. doi: 10.1007/s00401-017-1800-0. Epub 2017 Dec 29. PubMed PMID: 29288440.

21: Waitkus MS, Pirozzi CJ, Moure CJ, Diplas BH, Hansen LJ, Carpenter AB, Yang R, Wang Z, Ingram BO, Karoly ED, Mohney RP, Spasojevic I, McLendon RE, Friedman HS, He Y, Bigner DD, Yan H. Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1(R132H)-Induced Metabolic Liabilities. Cancer Res. 2018 Jan 1;78(1):36-50. doi: 10.1158/0008-5472.CAN-17-1352. Epub 2017 Nov 2. PubMed PMID: 29097607; PubMed Central PMCID: PMC5754242.

22: Karpel-Massler G, Ishida CT, Bianchetti E, Zhang Y, Shu C, Tsujiuchi T, Banu MA, Garcia F, Roth KA, Bruce JN, Canoll P, Siegelin MD. Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL. Nat Commun. 2017 Oct 20;8(1):1067. doi: 10.1038/s41467-017-00984-9. PubMed PMID: 29057925; PubMed Central PMCID: PMC5651864.

23: Wenger KJ, Hattingen E, Franz K, Steinbach J, Bähr O, Pilatus U. In vivo Metabolic Profiles as Determined by (31)P and short TE (1)H MR-Spectroscopy : No Difference Between Patients with IDH Wildtype and IDH Mutant Gliomas. Clin Neuroradiol. 2019 Mar;29(1):27-36. doi: 10.1007/s00062-017-0630-8. Epub 2017 Oct 5. PubMed PMID: 28983683.

24: Natsumeda M, Motohashi K, Igarashi H, Nozawa T, Abe H, Tsukamoto Y, Ogura R, Okada M, Kobayashi T, Aoki H, Takahashi H, Kakita A, Okamoto K, Nakada T, Fujii Y. Reliable diagnosis of IDH-mutant glioblastoma by 2-hydroxyglutarate detection: a study by 3-T magnetic resonance spectroscopy. Neurosurg Rev. 2018 Apr;41(2):641-647. doi: 10.1007/s10143-017-0908-y. Epub 2017 Sep 27. PubMed PMID: 28956184.

25: Mazor T, Chesnelong C, Pankov A, Jalbert LE, Hong C, Hayes J, Smirnov IV, Marshall R, Souza CF, Shen Y, Viswanath P, Noushmehr H, Ronen SM, Jones SJM, Marra MA, Cairncross JG, Perry A, Nelson SJ, Chang SM, Bollen AW, Molinaro AM, Bengtsson H, Olshen AB, Weiss S, Phillips JJ, Luchman HA, Costello JF. Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1. Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):10743-10748. doi: 10.1073/pnas.1708914114. Epub 2017 Sep 15. PubMed PMID: 28916733; PubMed Central PMCID: PMC5635900.

26: Molenaar RJ, Coelen RJS, Khurshed M, Roos E, Caan MWA, van Linde ME, Kouwenhoven M, Bramer JAM, Bovée JVMG, Mathôt RA, Klümpen HJ, van Laarhoven HWM, van Noorden CJF, Vandertop WP, Gelderblom H, van Gulik TM, Wilmink JW. Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours. BMJ Open. 2017 Jun 10;7(6):e014961. doi: 10.1136/bmjopen-2016-014961. PubMed PMID: 28601826; PubMed Central PMCID: PMC5541450.

27: Yang Z, Jiang B, Wang Y, Ni H, Zhang J, Xia J, Shi M, Hung LM, Ruan J, Mak TW, Li Q, Han J. 2-HG Inhibits Necroptosis by Stimulating DNMT1-Dependent Hypermethylation of the RIP3 Promoter. Cell Rep. 2017 May 30;19(9):1846-1857. doi: 10.1016/j.celrep.2017.05.012. PubMed PMID: 28564603.

28: Chen H, Judkins J, Thomas C, Wu M, Khoury L, Benjamin CG, Pacione D, Golfinos JG, Kumthekar P, Ghamsari F, Chen L, Lein P, Chetkovich DM, Snuderl M, Horbinski C. Mutant IDH1 and seizures in patients with glioma. Neurology. 2017 May 9;88(19):1805-1813. doi: 10.1212/WNL.0000000000003911. Epub 2017 Apr 12. PubMed PMID: 28404805; PubMed Central PMCID: PMC5419985.

29: Jiang B, Zhang J, Xia J, Zhao W, Wu Y, Shi M, Luo L, Zhou H, Chen A, Ma H, Zhao Q, Suleman M, Lin F, Zhou L, Wang J, Zhang Y, He Y, Li X, Hung LM, Mak TW, Li Q. IDH1 Mutation Promotes Tumorigenesis by Inhibiting JNK Activation and Apoptosis Induced by Serum Starvation. Cell Rep. 2017 Apr 11;19(2):389-400. doi: 10.1016/j.celrep.2017.03.053. PubMed PMID: 28402860.

30: Sulkowski PL, Corso CD, Robinson ND, Scanlon SE, Purshouse KR, Bai H, Liu Y, Sundaram RK, Hegan DC, Fons NR, Breuer GA, Song Y, Mishra-Gorur K, De Feyter HM, de Graaf RA, Surovtseva YV, Kachman M, Halene S, Günel M, Glazer PM, Bindra RS. 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. Sci Transl Med. 2017 Feb 1;9(375). pii: eaal2463. doi: 10.1126/scitranslmed.aal2463. PubMed PMID: 28148839; PubMed Central PMCID: PMC5435119.

31: Pirozzi CJ, Carpenter AB, Waitkus MS, Wang CY, Zhu H, Hansen LJ, Chen LH, Greer PK, Feng J, Wang Y, Bock CB, Fan P, Spasojevic I, McLendon RE, Bigner DD, He Y, Yan H. Mutant IDH1 Disrupts the Mouse Subventricular Zone and Alters Brain Tumor Progression. Mol Cancer Res. 2017 May;15(5):507-520. doi: 10.1158/1541-7786.MCR-16-0485. Epub 2017 Feb 1. PubMed PMID: 28148827; PubMed Central PMCID: PMC5415422.

32: Pusch S, Krausert S, Fischer V, Balss J, Ott M, Schrimpf D, Capper D, Sahm F, Eisel J, Beck AC, Jugold M, Eichwald V, Kaulfuss S, Panknin O, Rehwinkel H, Zimmermann K, Hillig RC, Guenther J, Toschi L, Neuhaus R, Haegebart A, Hess-Stumpp H, Bauser M, Wick W, Unterberg A, Herold-Mende C, Platten M, von Deimling A. Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. Acta Neuropathol. 2017 Apr;133(4):629-644. doi: 10.1007/s00401-017-1677-y. Epub 2017 Jan 25. PubMed PMID: 28124097.

33: Unruh D, Schwarze SR, Khoury L, Thomas C, Wu M, Chen L, Chen R, Liu Y, Schwartz MA, Amidei C, Kumthekar P, Benjamin CG, Song K, Dawson C, Rispoli JM, Fatterpekar G, Golfinos JG, Kondziolka D, Karajannis M, Pacione D, Zagzag D, McIntyre T, Snuderl M, Horbinski C. Mutant IDH1 and thrombosis in gliomas. Acta Neuropathol. 2016 Dec;132(6):917-930. Epub 2016 Sep 23. PubMed PMID: 27664011; PubMed Central PMCID: PMC5640980.

34: Carbonneau M, M Gagné L, Lalonde ME, Germain MA, Motorina A, Guiot MC, Secco B, Vincent EE, Tumber A, Hulea L, Bergeman J, Oppermann U, Jones RG, Laplante M, Topisirovic I, Petrecca K, Huot MÉ, Mallette FA. The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway. Nat Commun. 2016 Sep 14;7:12700. doi: 10.1038/ncomms12700. PubMed PMID: 27624942; PubMed Central PMCID: PMC5027283.

35: Lombardi G, Della Puppa A, Zagonel V. Urine 2-Hydroxyglutarate in Glioma. Oncologist. 2016 Aug;21(8):1026. doi: 10.1634/theoncologist.2016-0123. PubMed PMID: 27507897; PubMed Central PMCID: PMC4978559.

36: Jafari-Khouzani K, Loebel F, Bogner W, Rapalino O, Gonzalez GR, Gerstner E, Chi AS, Batchelor TT, Rosen BR, Unkelbach J, Shih HA, Cahill DP, Andronesi OC. Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients. Neuro Oncol. 2016 Nov;18(11):1569-1578. Epub 2016 Jul 5. PubMed PMID: 27382115; PubMed Central PMCID: PMC5063518.

37: Kalinina J, Ahn J, Devi NS, Wang L, Li Y, Olson JJ, Glantz M, Smith T, Kim EL, Giese A, Jensen RL, Chen CC, Carter BS, Mao H, He M, Van Meir EG. Selective Detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of Glioma Patients with Mutated Isocitrate Dehydrogenase. Clin Cancer Res. 2016 Dec 15;22(24):6256-6265. Epub 2016 Jun 23. PubMed PMID: 27340277; PubMed Central PMCID: PMC5443654.

38: Wang HY, Tang K, Liang TY, Zhang WZ, Li JY, Wang W, Hu HM, Li MY, Wang HQ, He XZ, Zhu ZY, Liu YW, Zhang SZ. The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas. J Exp Clin Cancer Res. 2016 May 31;35:86. doi: 10.1186/s13046-016-0362-7. PubMed PMID: 27245697; PubMed Central PMCID: PMC4888668.

39: Nagashima H, Tanaka K, Sasayama T, Irino Y, Sato N, Takeuchi Y, Kyotani K, Mukasa A, Mizukawa K, Sakata J, Yamamoto Y, Hosoda K, Itoh T, Sasaki R, Kohmura E. Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma. Neuro Oncol. 2016 Nov;18(11):1559-1568. Epub 2016 May 5. PubMed PMID: 27154922; PubMed Central PMCID: PMC5063515.

40: Voelxen NF, Walenta S, Proescholdt M, Dettmer K, Pusch S, Mueller-Klieser W. Quantitative Imaging of D-2-Hydroxyglutarate in Selected Histological Tissue Areas by a Novel Bioluminescence Technique. Front Oncol. 2016 Mar 7;6:46. doi: 10.3389/fonc.2016.00046. eCollection 2016. PubMed PMID: 27014623; PubMed Central PMCID: PMC4779886.

41: Bisdas S, Chadzynski GL, Braun C, Schittenhelm J, Skardelly M, Hagberg GE, Ethofer T, Pohmann R, Shajan G, Engelmann J, Tabatabai G, Ziemann U, Ernemann U, Scheffler K. MR spectroscopy for in vivo assessment of the oncometabolite 2-hydroxyglutarate and its effects on cellular metabolism in human brain gliomas at 9.4T. J Magn Reson Imaging. 2016 Oct;44(4):823-33. doi: 10.1002/jmri.25221. Epub 2016 Mar 11. PubMed PMID: 26970248.

42: Fathi AT, Nahed BV, Wander SA, Iafrate AJ, Borger DR, Hu R, Thabet A, Cahill DP, Perry AM, Joseph CP, Muzikansky A, Chi AS. Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma. Oncologist. 2016 Feb;21(2):214-9. doi: 10.1634/theoncologist.2015-0342. Epub 2016 Feb 1. PubMed PMID: 26834160; PubMed Central PMCID: PMC4746092.

43: Heo H, Kim S, Lee HH, Cho HR, Xu WJ, Lee SH, Park CK, Park S, Choi SH, Kim H. On the Utility of Short Echo Time (TE) Single Voxel 1H-MRS in Non-Invasive Detection of 2-Hydroxyglutarate (2HG); Challenges and Potential Improvement Illustrated with Animal Models Using MRUI and LCModel. PLoS One. 2016 Jan 28;11(1):e0147794. doi: 10.1371/journal.pone.0147794. eCollection 2016. PubMed PMID: 26820720; PubMed Central PMCID: PMC4731570.

44: Flavahan WA, Drier Y, Liau BB, Gillespie SM, Venteicher AS, Stemmer-Rachamimov AO, Suvà ML, Bernstein BE. Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature. 2016 Jan 7;529(7584):110-4. doi: 10.1038/nature16490. Epub 2015 Dec 23. PubMed PMID: 26700815; PubMed Central PMCID: PMC4831574.

45: de la Fuente MI, Young RJ, Rubel J, Rosenblum M, Tisnado J, Briggs S, Arevalo-Perez J, Cross JR, Campos C, Straley K, Zhu D, Dong C, Thomas A, Omuro AA, Nolan CP, Pentsova E, Kaley TJ, Oh JH, Noeske R, Maher E, Choi C, Gutin PH, Holodny AI, Yen K, DeAngelis LM, Mellinghoff IK, Thakur SB. Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. Neuro Oncol. 2016 Feb;18(2):283-90. doi: 10.1093/neuonc/nov307. Epub 2015 Dec 20. PubMed PMID: 26691210; PubMed Central PMCID: PMC4724186.

46: Wang P, Wu J, Ma S, Zhang L, Yao J, Hoadley KA, Wilkerson MD, Perou CM, Guan KL, Ye D, Xiong Y. Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents. Cell Rep. 2015 Dec 22;13(11):2353-2361. doi: 10.1016/j.celrep.2015.11.029. Epub 2015 Dec 10. PubMed PMID: 26686626; PubMed Central PMCID: PMC4694633.

47: Tateishi K, Wakimoto H, Iafrate AJ, Tanaka S, Loebel F, Lelic N, Wiederschain D, Bedel O, Deng G, Zhang B, He T, Shi X, Gerszten RE, Zhang Y, Yeh JJ, Curry WT, Zhao D, Sundaram S, Nigim F, Koerner MVA, Ho Q, Fisher DE, Roider EM, Kemeny LV, Samuels Y, Flaherty KT, Batchelor TT, Chi AS, Cahill DP. Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. Cancer Cell. 2015 Dec 14;28(6):773-784. doi: 10.1016/j.ccell.2015.11.006. PubMed PMID: 26678339; PubMed Central PMCID: PMC4684594.

48: Emir UE, Larkin SJ, de Pennington N, Voets N, Plaha P, Stacey R, Al-Qahtani K, Mccullagh J, Schofield CJ, Clare S, Jezzard P, Cadoux-Hudson T, Ansorge O. Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations. Cancer Res. 2016 Jan 1;76(1):43-9. doi: 10.1158/0008-5472.CAN-15-0934. Epub 2015 Dec 15. PubMed PMID: 26669865; PubMed Central PMCID: PMC4704134.

49: Andronesi OC, Loebel F, Bogner W, Marjańska M, Vander Heiden MG, Iafrate AJ, Dietrich J, Batchelor TT, Gerstner ER, Kaelin WG, Chi AS, Rosen BR, Cahill DP. Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate. Clin Cancer Res. 2016 Apr 1;22(7):1632-41. doi: 10.1158/1078-0432.CCR-15-0656. Epub 2015 Nov 3. PubMed PMID: 26534967; PubMed Central PMCID: PMC4818725.

50: Fujii Y, Ogasawara S, Oki H, Liu X, Kaneko MK, Takano S, Kato Y. A high-sensitive HMab-2 specifically detects IDH1-R132H, the most common IDH mutation in gliomas. Biochem Biophys Res Commun. 2015 Oct 30;466(4):733-9. doi: 10.1016/j.bbrc.2015.09.070. Epub 2015 Sep 14. PubMed PMID: 26381180.

51: Molenaar RJ, Botman D, Smits MA, Hira VV, van Lith SA, Stap J, Henneman P, Khurshed M, Lenting K, Mul AN, Dimitrakopoulou D, van Drunen CM, Hoebe RA, Radivoyevitch T, Wilmink JW, Maciejewski JP, Vandertop WP, Leenders WP, Bleeker FE, van Noorden CJ. Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198. Cancer Res. 2015 Nov 15;75(22):4790-802. doi: 10.1158/0008-5472.CAN-14-3603. Epub 2015 Sep 11. PubMed PMID: 26363012.

52: Fu X, Chin RM, Vergnes L, Hwang H, Deng G, Xing Y, Pai MY, Li S, Ta L, Fazlollahi F, Chen C, Prins RM, Teitell MA, Nathanson DA, Lai A, Faull KF, Jiang M, Clarke SG, Cloughesy TF, Graeber TG, Braas D, Christofk HR, Jung ME, Reue K, Huang J. 2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling. Cell Metab. 2015 Sep 1;22(3):508-15. doi: 10.1016/j.cmet.2015.06.009. Epub 2015 Jul 16. PubMed PMID: 26190651; PubMed Central PMCID: PMC4663076.

53: Lombardi G, Corona G, Bellu L, Della Puppa A, Pambuku A, Fiduccia P, Bertorelle R, Gardiman MP, D'Avella D, Toffoli G, Zagonel V. Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma. Oncologist. 2015 May;20(5):562-7. doi: 10.1634/theoncologist.2014-0266. Epub 2015 Apr 10. PubMed PMID: 25862748; PubMed Central PMCID: PMC4425377.

54: Chen R, Ravindra VM, Cohen AL, Jensen RL, Salzman KL, Prescot AP, Colman H. Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas. Neurosurg Focus. 2015 Mar;38(3):E2. doi: 10.3171/2015.1.FOCUS14745. Review. PubMed PMID: 25727224.

55: Natsumeda M, Igarashi H, Nomura T, Ogura R, Tsukamoto Y, Kobayashi T, Aoki H, Okamoto K, Kakita A, Takahashi H, Nakada T, Fujii Y. Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-tesla magnetic resonance spectroscopy. Acta Neuropathol Commun. 2014 Nov 7;2:158. doi: 10.1186/s40478-014-0158-y. PubMed PMID: 25376594; PubMed Central PMCID: PMC4236810.

56: Santagata S, Eberlin LS, Norton I, Calligaris D, Feldman DR, Ide JL, Liu X, Wiley JS, Vestal ML, Ramkissoon SH, Orringer DA, Gill KK, Dunn IF, Dias-Santagata D, Ligon KL, Jolesz FA, Golby AJ, Cooks RG, Agar NY. Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery. Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):11121-6. doi: 10.1073/pnas.1404724111. Epub 2014 Jun 30. PubMed PMID: 24982150; PubMed Central PMCID: PMC4121790.

57: Ohka F, Ito M, Ranjit M, Senga T, Motomura A, Motomura K, Saito K, Kato K, Kato Y, Wakabayashi T, Soga T, Natsume A. Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation. Tumour Biol. 2014 Jun;35(6):5911-20. doi: 10.1007/s13277-014-1784-5. Epub 2014 Mar 5. PubMed PMID: 24590270.

58: Juratli TA, Peitzsch M, Geiger K, Schackert G, Eisenhofer G, Krex D. Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas. Neuro Oncol. 2013 Jun;15(6):682-90. doi: 10.1093/neuonc/not006. Epub 2013 Feb 14. PubMed PMID: 23410661; PubMed Central PMCID: PMC3661092.

59: Kalinina J, Carroll A, Wang L, Yu Q, Mancheno DE, Wu S, Liu F, Ahn J, He M, Mao H, Van Meir EG. Detection of “oncometabolite” 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma. J Mol Med (Berl). 2012 Oct;90(10):1161-1171. doi: 10.1007/s00109-012-0888-x. Epub 2012 Mar 17. PubMed PMID: 22426639; PubMed Central PMCID: PMC4147374.

60: Yu L, Qi ST, Li ZY. Analysis of isocitrate dehydrogenase-1/2 gene mutations in gliomas. Chin Med J (Engl). 2010 Dec;123(24):3697-705. Review. PubMed PMID: 22166653.

61: Borodovsky A, Seltzer MJ, Riggins GJ. Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2. Curr Opin Oncol. 2012 Jan;24(1):83-9. doi: 10.1097/CCO.0b013e32834d816a. Review. PubMed PMID: 22080945; PubMed Central PMCID: PMC4612588.

62: Seltzer MJ, Bennett BD, Joshi AD, Gao P, Thomas AG, Ferraris DV, Tsukamoto T, Rojas CJ, Slusher BS, Rabinowitz JD, Dang CV, Riggins GJ. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 2010 Nov 15;70(22):8981-7. doi: 10.1158/0008-5472.CAN-10-1666. Epub 2010 Nov 2. PubMed PMID: 21045145; PubMed Central PMCID: PMC3058858.

63: Komotar RJ, Starke RM, Sisti MB, Connolly ES. IDH1 and IDH2 mutations in gliomas and the associated induction of hypoxia-inducible factor and production of 2-hydroxyglutarate. Neurosurgery. 2010 Apr;66(4):N20-1. doi: 10.1227/01.neu.0000369899.41915.67. PubMed PMID: 20305482.

Li X, Strasser B, Jafari-Khouzani K, Thapa B, Small J, Cahill DP, Dietrich J, Batchelor TT, Andronesi OC. Super-Resolution Whole-Brain 3D MR Spectroscopic Imaging for Mapping D-2-Hydroxyglutarate and Tumor Metabolism in Isocitrate Dehydrogenase 1-mutated Human Gliomas. Radiology. 2020 Jan 7:191529. doi: 10.1148/radiol.2020191529. [Epub ahead of print] PubMed PMID: 31909698.
Lu J, Li D, Zeng Y, Wang H, Feng W, Qi S, Yu L. IDH1 mutation promotes proliferation and migration of glioma cells via EMT induction. J BUON. 2019 Nov-Dec;24(6):2458-2464. PubMed PMID: 31983120.
Lu AY, Damisah EC, Winkler EA, Grant RA, Eid T, Bulsara KR. Cerebrospinal fluid untargeted metabolomic profiling of aneurysmal subarachnoid hemorrhage: an exploratory study. Br J Neurosurg. 2018 Dec 26:1-5. doi: 10.1080/02688697.2018.1519107. [Epub ahead of print] PubMed PMID: 30585503.
  • d-2-hydroxyglutarate.txt
  • Last modified: 2020/01/27 17:50
  • by administrador